Attempts to Regulate Drug Pricing Fail During Legislative Chaos

December 31, 2024

Drug Pricing Reforms Stalled Amid Legislative Hurdles and Opposition

In an attempt to address high, out-of-pocket drug prices, Democrats attempted to push through several piece of legislation that would have placed burdensome restrictions on drug manufacturers.


One measure, HB 5350, would have required drug manufacturers to provide drug products to contract pharmacies participating in a 340B program without conditions or limitations, and thereby alter a federal program at the state level. SB 1179, a companion bill introduced by Sen. Singh in the lame duck session, was rammed through Committee, despite opposition from MichBio, BIO, PhRMA, and patient groups, and then garnered full Senate passage only to falter in the House due to that chamber’s inaction.



Legislation to establish a Prescription Drug Affordability Program (PDAB), SB 483, passed the Michigan Senate in 2023 and carried over into 2024 where the bill sat in the House. Such a state-run board would be tasked with conducting cost analysis on prescription drugs and then imposing a reimbursement limit (upper payment limit-UPL) on therapies the PDAB determines are unaffordable to the consumer and/or state health care system. Unfortunately, the legislation would not alter out-of-pockets whatsoever and many patient groups, especially those from the rare disease community, were adamantly opposed. MichBio and BIO slowed the bill by convincing a small group of legislators to oppose the measure. It too died in session when the House couldn’t move it forward.

RECENT ARTICLES

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms
April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .
April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.